search
Back to results

Study for the RevLite Laser System for Facial Solar Lentigines

Primary Purpose

Facial Solar Lentigines

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Revlite Laser System
Sponsored by
Cynosure, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional device feasibility trial for Facial Solar Lentigines

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Is a healthy male or female between 18 and 60 years old.
  2. Is Fitzpatrick Skin types I-III
  3. Is willing to consent to participate in the study.
  4. Is willing to comply with all requirements of the study including being photographed, following post treatment care and attending all treatment and follow up visits.
  5. Has clinically determined mild to severe facial mottled pigmentation (solar lentigines) on the face.

Exclusion Criteria:

  1. Is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period.
  2. Is hypersensitive to light exposure OR takes photo sensitized medication.
  3. Has active or localized systemic infections.
  4. Has a coagulation disorder or is currently using anti-coagulation medication (including but not limited to the heavy use of aspirin {greater than 81 mg per day}).
  5. Has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study.
  6. Is currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within 3 months prior to entering this study.
  7. Has used Accutane within 6 months prior to enrollment.
  8. Has the need to be exposed to artificial tanning devices or excessive sunlight during the trial.
  9. Has had prior treatment with parenteral gold therapy (gold sodium thiomalate).
  10. Has a history of keloids.
  11. Has evidence of compromised wound healing.
  12. Has a history of basal cell carcinoma, squamous cell carcinoma or melanoma.
  13. Has a history of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications or has an autoimmune disorder.

Sites / Locations

  • Sadick Research Group

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Revlite Laser System- Single Wavelength

Revlite Laser System- Dual Wavelength

Arm Description

Revlite Laser System- 1064nm wavelength will be used on half of the face.

Revlite Laser System- treatment will consist of 1064 nm and 532 nm wavelengths on half of the face.

Outcomes

Primary Outcome Measures

Photographic Evaluation Using the Blinded Global Aesthetic Improvement Scale
Photos taken at baseline will be compared to photos taken 1 month post last treatment to assess the level of improvement using the Global Aesthetic Improvement Scale. This evaluation is blinded. This scale ranges from -1 to 3, where -1 is worsened, 0 is no change, 1 is improved, 2 is much improved, and 3 is very much improved.

Secondary Outcome Measures

Physician Satisfaction Questionnaire
The satisfaction is on a scale ranging from extremely satisfied (6) to extremely dissatisfied (1).

Full Information

First Posted
April 8, 2014
Last Updated
November 24, 2021
Sponsor
Cynosure, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02110108
Brief Title
Study for the RevLite Laser System for Facial Solar Lentigines
Official Title
Study for the RevLite Laser System for Facial Solar Lentigines
Study Type
Interventional

2. Study Status

Record Verification Date
November 2021
Overall Recruitment Status
Completed
Study Start Date
March 2014 (undefined)
Primary Completion Date
February 2015 (Actual)
Study Completion Date
February 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Cynosure, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the effects of the Revlite Laser System for treatment of facial solar lentigines
Detailed Description
Prospective facial study using the revlite laser to treat pigmentation caused by sun damage.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Facial Solar Lentigines

7. Study Design

Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Each patient receives a single wavelength treatment on one side of their face, and a double wavelength on the other side of their face.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Revlite Laser System- Single Wavelength
Arm Type
Experimental
Arm Description
Revlite Laser System- 1064nm wavelength will be used on half of the face.
Arm Title
Revlite Laser System- Dual Wavelength
Arm Type
Experimental
Arm Description
Revlite Laser System- treatment will consist of 1064 nm and 532 nm wavelengths on half of the face.
Intervention Type
Device
Intervention Name(s)
Revlite Laser System
Intervention Description
Revlite Laser System for the Treatment of Facial Solar Lentigines
Primary Outcome Measure Information:
Title
Photographic Evaluation Using the Blinded Global Aesthetic Improvement Scale
Description
Photos taken at baseline will be compared to photos taken 1 month post last treatment to assess the level of improvement using the Global Aesthetic Improvement Scale. This evaluation is blinded. This scale ranges from -1 to 3, where -1 is worsened, 0 is no change, 1 is improved, 2 is much improved, and 3 is very much improved.
Time Frame
1 month post last treatment
Secondary Outcome Measure Information:
Title
Physician Satisfaction Questionnaire
Description
The satisfaction is on a scale ranging from extremely satisfied (6) to extremely dissatisfied (1).
Time Frame
1 month post last treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Is a healthy male or female between 18 and 60 years old. Is Fitzpatrick Skin types I-III Is willing to consent to participate in the study. Is willing to comply with all requirements of the study including being photographed, following post treatment care and attending all treatment and follow up visits. Has clinically determined mild to severe facial mottled pigmentation (solar lentigines) on the face. Exclusion Criteria: Is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period. Is hypersensitive to light exposure OR takes photo sensitized medication. Has active or localized systemic infections. Has a coagulation disorder or is currently using anti-coagulation medication (including but not limited to the heavy use of aspirin {greater than 81 mg per day}). Has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study. Is currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within 3 months prior to entering this study. Has used Accutane within 6 months prior to enrollment. Has the need to be exposed to artificial tanning devices or excessive sunlight during the trial. Has had prior treatment with parenteral gold therapy (gold sodium thiomalate). Has a history of keloids. Has evidence of compromised wound healing. Has a history of basal cell carcinoma, squamous cell carcinoma or melanoma. Has a history of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications or has an autoimmune disorder.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Patricia Krantz
Organizational Affiliation
Cynosure, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Sadick Research Group
City
New York
State/Province
New York
ZIP/Postal Code
10075
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Study for the RevLite Laser System for Facial Solar Lentigines

We'll reach out to this number within 24 hrs